Technical Analysis for TERN - Terns Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 6.94 1.17% 0.08
TERN closed up 1.17 percent on Friday, November 1, 2024, on 41 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: Nov 12
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Flat

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.17%
Inside Day Range Contraction 1.17%
Gapped Up Strength 1.17%
200 DMA Resistance Bearish 0.73%
Slingshot Bearish Bearish Swing Setup 0.73%
Lower Bollinger Band Walk Weakness 0.73%
Oversold Stochastic Weakness 0.73%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 22 hours ago
60 Minute Opening Range Breakout about 23 hours ago
200 DMA Resistance about 23 hours ago
Rose Above Previous Day's High about 23 hours ago
Rose Above 200 DMA about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Terns Pharmaceuticals, Inc. Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Glucagon Bile Acid Chronic Liver Diseases Anti Diabetic Drugs

Is TERN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.4
52 Week Low 3.26
Average Volume 2,159,271
200-Day Moving Average 7.05
50-Day Moving Average 8.17
20-Day Moving Average 7.28
10-Day Moving Average 6.92
Average True Range 0.47
RSI (14) 39.39
ADX 26.2
+DI 13.66
-DI 22.66
Chandelier Exit (Long, 3 ATRs) 7.05
Chandelier Exit (Short, 3 ATRs) 7.81
Upper Bollinger Bands 8.12
Lower Bollinger Band 6.44
Percent B (%b) 0.3
BandWidth 23.11
MACD Line -0.41
MACD Signal Line -0.41
MACD Histogram -0.0065
Fundamentals Value
Market Cap 428.85 Million
Num Shares 61.8 Million
EPS -1.15
Price-to-Earnings (P/E) Ratio -6.03
Price-to-Sales 302.64
Price-to-Book 1.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.41
Resistance 3 (R3) 7.41 7.25 7.33
Resistance 2 (R2) 7.25 7.13 7.25 7.30
Resistance 1 (R1) 7.10 7.06 7.18 7.10 7.28
Pivot Point 6.94 6.94 6.98 6.94 6.94
Support 1 (S1) 6.79 6.82 6.87 6.79 6.60
Support 2 (S2) 6.63 6.75 6.63 6.58
Support 3 (S3) 6.48 6.63 6.55
Support 4 (S4) 6.48